Clinical Trial Update: The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD [Phase 2]

View source ↗

Summary

This update reports Phase 2 trial results for CP-101,606, an NMDA receptor antagonist, in patients with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CP-101,606 (CP-101,606)

Snippet

Sponsor: Pfizer | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED